Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Moore

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Biomedical Materials Research. Part A|May 25, 2012
Mass transfer trends occurring in engineered ex vivo tissue scaffoldsMarc Moore, Malisa Sarntinoranont, Peter McFetridge
Tissue Engineering. Part A|April 2, 2013
Directed oxygen gradients initiate a robust early remodeling response in engineered vascular graftsMarc Moore, Ruben Moore, Peter S McFetridge
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 15, 2016
Current Progress in Therapeutic Gene Editing for Monogenic DiseasesVersha Prakash, Marc Moore, Rafael J Yáñez-Muñoz
Molecular Therapy. Methods & Clinical Development|May 26, 2022
Optimized lentiviral vector to restore full-length dystrophin via a cell-mediated approach in a mouse model of Duchenne muscular dystrophyJinhong Meng, Marc Moore, John Counsell, et al.
Skeletal Muscle|November 29, 2024
Golodirsen restores DMD transcript imbalance in Duchenne Muscular Dystrophy patient muscle cellsRachele Rossi, Silvia Torelli, Marc Moore, et al.
Journal of Personalized Medicine|December 24, 2021
Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489CElias K Awad, Marc Moore, Hui Liu, et al.
Molecular Therapy. Methods & Clinical Development|February 8, 2021
Re-structuring lentiviral vectors to express genomic RNA via cap-dependent translationJohn R Counsell, Guillaume De Brabandere, Rajvinder Karda, et al.
Nucleic Acids Research|December 20, 2015
piggyBac transposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblastsMariana Loperfido, Susan Jarmin, Sumitava Dastidar, et al.
Molecular Therapy. Nucleic Acids|April 18, 2022
Targeted exon skipping of <i>NF1</i> exon 17 as a therapeutic for neurofibromatosis type IAndré Leier, Marc Moore, Hui Liu, et al.
EMBO Molecular Medicine|December 16, 2017
Reversible immortalisation enables genetic correction of human muscle progenitors and engineering of next-generation human artificial chromosomes for Duchenne muscular dystrophySara Benedetti, Narumi Uno, Hidetoshi Hoshiya, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Biomedical Materials Research. Part A|May 25, 2012
Mass transfer trends occurring in engineered ex vivo tissue scaffoldsMarc Moore, Malisa Sarntinoranont, Peter McFetridge
Tissue Engineering. Part A|April 2, 2013
Directed oxygen gradients initiate a robust early remodeling response in engineered vascular graftsMarc Moore, Ruben Moore, Peter S McFetridge
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 15, 2016
Current Progress in Therapeutic Gene Editing for Monogenic DiseasesVersha Prakash, Marc Moore, Rafael J Yáñez-Muñoz
Molecular Therapy. Methods & Clinical Development|May 26, 2022
Optimized lentiviral vector to restore full-length dystrophin via a cell-mediated approach in a mouse model of Duchenne muscular dystrophyJinhong Meng, Marc Moore, John Counsell, et al.
Skeletal Muscle|November 29, 2024
Golodirsen restores DMD transcript imbalance in Duchenne Muscular Dystrophy patient muscle cellsRachele Rossi, Silvia Torelli, Marc Moore, et al.
Journal of Personalized Medicine|December 24, 2021
Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489CElias K Awad, Marc Moore, Hui Liu, et al.
Molecular Therapy. Methods & Clinical Development|February 8, 2021
Re-structuring lentiviral vectors to express genomic RNA via cap-dependent translationJohn R Counsell, Guillaume De Brabandere, Rajvinder Karda, et al.
Nucleic Acids Research|December 20, 2015
piggyBac transposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblastsMariana Loperfido, Susan Jarmin, Sumitava Dastidar, et al.
Molecular Therapy. Nucleic Acids|April 18, 2022
Targeted exon skipping of <i>NF1</i> exon 17 as a therapeutic for neurofibromatosis type IAndré Leier, Marc Moore, Hui Liu, et al.
EMBO Molecular Medicine|December 16, 2017
Reversible immortalisation enables genetic correction of human muscle progenitors and engineering of next-generation human artificial chromosomes for Duchenne muscular dystrophySara Benedetti, Narumi Uno, Hidetoshi Hoshiya, et al.
Pageof 1